KalVista Pharmaceuticals Inc. (NASDAQ: KALV) has announced a proposed private offering of $110 million aggregate principal amount of Convertible Senior Notes due 2031. The notes will be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. KalVista has also granted initial purchasers an option to purchase up to an additional $15 million aggregate principal amount of notes within 13 days of the initial issuance. The interest rate, initial conversion rate, offering price, and other terms will be determined upon pricing of the notes. The proceeds are intended for working capital, general corporate purposes, and potential future investments or acquisitions. Holders will have repurchase rights upon a fundamental change, and the conversion rate may increase in certain circumstances. The full prospectus URL is not included in the document.